HC Wainwright Has Negative Outlook for ONCY Q3 Earnings

Key Points

• HC Wainwright has revised its Q3 2025 earnings per share (EPS) estimate for Oncolytics Biotech from ($0.11) to ($0.12), while maintaining a "Buy" rating and a target price of $5.00.
• As of the latest reports, analysts have a consensus rating of "Moderate Buy" for Oncolytics Biotech, with a target price averaging $5.00.
• Oncolytics Biotech recently reported a better-than-expected Q2 EPS of ($0.05), exceeding the consensus estimate of ($0.11).

Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) - Analysts at HC Wainwright lowered their Q3 2025 EPS estimates for Oncolytics Biotech in a report released on Tuesday, September 16th. HC Wainwright analyst P. Trucchio now expects that the company will post earnings of ($0.12) per share for the quarter, down from their previous estimate of ($0.11). The consensus estimate for Oncolytics Biotech's current full-year earnings is ($0.28) per share. HC Wainwright also issued estimates for Oncolytics Biotech's FY2025 earnings at ($0.28) EPS.

Oncolytics Biotech (NASDAQ:ONCY - Get Free Report) last issued its earnings results on Friday, August 8th. The company reported ($0.05) EPS for the quarter, topping the consensus estimate of ($0.11) by $0.06.

Other analysts have also recently issued research reports about the company. Lake Street Capital initiated coverage on Oncolytics Biotech in a research report on Wednesday, August 13th. They issued a "buy" rating and a $7.00 target price for the company. Wall Street Zen raised Oncolytics Biotech from a "sell" rating to a "hold" rating in a research report on Saturday, August 16th. Four analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to MarketBeat, the company currently has an average rating of "Moderate Buy" and an average target price of $5.00.

Oncolytics Biotech Stock Down 4.4%

Shares of Oncolytics Biotech stock traded down $0.06 during midday trading on Thursday, hitting $1.30. The company's stock had a trading volume of 580,392 shares, compared to its average volume of 1,324,075. The firm has a market capitalization of $130.47 million, a P/E ratio of -4.81 and a beta of 1.19. The stock has a 50-day simple moving average of $1.11 and a 200-day simple moving average of $0.78. Oncolytics Biotech has a 1-year low of $0.33 and a 1-year high of $1.53.

Hedge Funds Weigh In On Oncolytics Biotech

An institutional investor recently raised its position in Oncolytics Biotech stock. Seeds Investor LLC grew its holdings in Oncolytics Biotech Inc. (NASDAQ:ONCY - Free Report) by 17.8% in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 223,767 shares of the company's stock after acquiring an additional 33,826 shares during the period. Seeds Investor LLC owned 0.23% of Oncolytics Biotech worth $173,000 as of its most recent SEC filing. Institutional investors and hedge funds own 6.82% of the company's stock.

About Oncolytics Biotech

Oncolytics Biotech Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of pharmaceutical products for the treatment of cancer. The company is developing pelareorep, an intravenously delivered immunotherapeutic agent, which is in phase 3 clinical trial for the treatment of hormone receptor-positive / human epidermal growth factor 2-negative metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma.